Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Denileukin diftitox (ONTAK) induces a tolerogenic phenotype in dendritic cells and stimulates survival of resting Treg.
Baur AS, Lutz MB, Schierer S, Beltrame L, Theiner G, Zinser E, Ostalecki C, Heidkamp G, Haendle I, Erdmann M, Wiesinger M, Leisgang W, Gross S, Pommer AJ, Kämpgen E, Dudziak D, Steinkasserer A, Cavalieri D, Schuler-Thurner B, Schuler G. Baur AS, et al. Blood. 2013 Sep 26;122(13):2185-94. doi: 10.1182/blood-2012-09-456988. Epub 2013 Aug 19. Blood. 2013. PMID: 23958949 Free article. Clinical Trial.
Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.
Gross S, Erdmann M, Haendle I, Voland S, Berger T, Schultz E, Strasser E, Dankerl P, Janka R, Schliep S, Heinzerling L, Sotlar K, Coulie P, Schuler G, Schuler-Thurner B. Gross S, et al. JCI Insight. 2017 Apr 20;2(8):e91438. doi: 10.1172/jci.insight.91438. eCollection 2017 Apr 20. JCI Insight. 2017. PMID: 28422751 Free PMC article.
Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein.
Buschow SI, Ramazzotti M, Reinieren-Beeren IMJ, Heinzerling LM, Westdorp H, Stefanini I, Beltrame L, Hato SV, Ellebaek E, Gross S, Nguyen VA, Weinlich G, Ragoussis J, Baban D, Schuler-Thurner B, Svane IM, Romani N, Austyn JM, De Vries IJM, Schuler G, Cavalieri D, Figdor CG. Buschow SI, et al. Oncotarget. 2017 Jun 27;8(40):67439-67456. doi: 10.18632/oncotarget.18698. eCollection 2017 Sep 15. Oncotarget. 2017. PMID: 28978044 Free PMC article.
Generation of an Oncolytic Herpes Simplex Virus 1 Expressing Human MelanA.
Boscheinen JB, Thomann S, Knipe DM, DeLuca N, Schuler-Thurner B, Gross S, Dörrie J, Schaft N, Bach C, Rohrhofer A, Werner-Klein M, Schmidt B, Schuster P. Boscheinen JB, et al. Front Immunol. 2019 Jan 22;10:2. doi: 10.3389/fimmu.2019.00002. eCollection 2019. Front Immunol. 2019. PMID: 30723467 Free PMC article.
Nectin-1 Expression Correlates with the Susceptibility of Malignant Melanoma to Oncolytic Herpes Simplex Virus In Vitro and In Vivo.
Schwertner B, Lindner G, Toledo Stauner C, Klapproth E, Magnus C, Rohrhofer A, Gross S, Schuler-Thurner B, Öttl V, Feichtgruber N, Drexler K, Evert K, Krahn MP, Berneburg M, Schmidt B, Schuster P, Haferkamp S. Schwertner B, et al. Cancers (Basel). 2021 Jun 19;13(12):3058. doi: 10.3390/cancers13123058. Cancers (Basel). 2021. PMID: 34205379 Free PMC article.
Comparison of the oncolytic activity of a replication-competent and a replication-deficient herpes simplex virus 1.
Lindner G, Walter A, Magnus CL, Rosenhammer K, Holoborodko B, Koch V, Hirsch S, Grossmann L, Li S, Knipe DM, DeLuca N, Schuler-Thurner B, Gross S, Schwertner B, Toelge M, Rohrhofer A, Stöckl S, Bauer RJ, Knoll G, Ehrenschwender M, Haferkamp S, Schmidt B, Schuster P. Lindner G, et al. Among authors: schuler thurner b. Immunology. 2024 Jun;172(2):279-294. doi: 10.1111/imm.13775. Epub 2024 Mar 5. Immunology. 2024. PMID: 38444199
79 results